PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US.
Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb. He currently serves as a member of the board of directors for Blueprint Medicines, Nabriva Therapeutics and Viking Therapeutics, with previous board appointments including Vitae Pharmaceuticals, BIND Therapeutics, Aurinia Pharmaceuticals and Idenix Pharmaceuticals, among others. He holds an M.B.A. from Rutgers University and a B.S. from Saint Joseph's University.
Duncan Higgons has most recently served as a member of the board of directors of Jounce Therapeutics since November 2015. He served as COO of Agios Therapeutics, Inc. from 2009 to 2016 where he was responsible for leading a transformative deal with Celgene and for building the company including a successful IPO. Before joining Agios he served as Executive Vice-President, and Interim President and CEO at Archemix Corporation from 2006 to 2009 and prior to that he served as the Chief Commercial Officer (CCO) at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company, which was acquired by Johnson & Johnson Company. Earlier in his career, he held roles of increasing seniority in strategic planning, marketing, sales and business development at Eli Lilly, Baxter and Alkermes, becoming Senior Vice President, Business Operations and Marketing at Alkermes where he negotiated numerous partnership and licensing deals. Duncan holds a B.Sc. in Mathematics from King’s College University of London and an M.Sc. in Economics from London Business School.
“I am delighted to welcome both Charlie and Duncan to strengthen the PsiOxus Board at this key stage of our growth,” stated Paolo Paoletti, Chairman of the PsiOxus Board of Directors “these two US based Board appointments are critical as PsiOxus continues to mature and internationalise”.
“Together with the recent opening of our facility near Philadelphia, the addition of two US based Board Directors is a continuation of our commitment to become an international biotech and a leader in oncolytic immunotherapy” added John Beadle, Chief Executive Officer. PsiOxus completed two deals with Bristol-Myers Squib (BMS) in 2017 including a transformative pre-clinical deal on NG-348, an innovative gene therapy product for cancer based upon the company’s Tumor-Specific Immuno-Gene therapy (T-SIGn) platform.
About PsiOxus Therapeutics Ltd.
PsiOxus Therapeutics is a development stage biotechnology company focused upon immune-oncology with headquarters near Oxford, UK and offices near Philadelphia, USA. PsiOxus has developed the proprietary Tumor-Specific Immuno-Gene therapy (T-SIGn) platform for systemic delivery of tumor-targeted oncolytic immune therapeutics. The T-SIGn platform is based on the company's oncolytic virus, enadenotucirev, which can be delivered by intravenous administration and replicates only in tumor cells. Enadenotucirev is currently in a clinical trial under a US IND in combination with nivolumab (Opdivo ®) in collaboration with Bristol-Myers Squib (BMS). The anticancer capability of the T-SIGn platform is further enhanced through “arming” the virus with transgenes. The armed T-SIGn platform makes possible creation of a broad range of systemically delivered oncolytic immune therapeutics including oncolytic viruses that express one or more antibodies, cytokines, immunomodulatory proteins, or nucleotide (RNA) based payloads. T-SIGn thus opens up the possibility of gene therapy for cancer. NG-348, the first T-SIGn product was licensed to BMS in 2017 with an upfront payment of $50million.
View this news release online at: www.psioxus.com
PsiOxus Therapeutics Ltd.
John Beadle, +44 1235 42 98 40
Burns McClellan, Inc., on behalf of PsiOxus
Ben Matone, 2122130006
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
LINTEC Announces Four New Adhesive Materials for Labels20.9.2017 10:45 | Pressemelding
LINTEC Corporation (TOKYO: 7966) announced on September 20 that it will launch four newly developed label adhesive materials sequentially from October 2017. The new products will be on display prior to launch at Labelexpo Europe 2017, the world’s largest trade show in the label field. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005611/en/ LINTEC's super-strength adhesive labelstocks (Photo: Business Wire) Overview of Labelexpo Europe 2017 Date: September 25 (Mon.) to 28 (Thurs.) Venue: Brussels Expo, Belgium LINTEC Booth: Hall 3 3C 15 LINTEC Press Conference: 11:00 a.m. to 11:30 a.m., September 25, held in the Brussels Expo Press Office Theater Super-strength adhesive labelstocks: Extreme adhesion for rough surfaces Charac
EGS Invests in Artificial Intelligence from Quintiq20.9.2017 10:05 | Pressemelding
Quintiq, a Dassault Systèmes brand and global leader in supply chain planning and optimization (SCP&O), announces that it has partnered with European Gateway Services (EGS) to bring a new level of intelligence to intermodal logistics. European Gateway Services (EGS) offers the market an integrated network for transport to and from the European hinterland. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005578/en/ EGS invests in artificial intelligence from Quintiq (Photo: Business Wire) To better support its customers, EGS takes standard planning strategies to a new level with a synchromodal trip optimizer using Quintiq’s planning and optimization software, which employs artificial intelligence to choose the optimal modes and routes at all times. Quintiq technology makes s
EchoStar 105/SES-11 Shipped from Toulouse to the Cape for SpaceX Launch20.9.2017 09:03 | Pressemelding
SES, EchoStar Corp., and Airbus Defence and Space announced today that the new EchoStar 105/SES-11 spacecraft, built by Airbus, has been shipped from the Airbus facilities in Toulouse, France, to Cape Canaveral, Florida, for its forthcoming launch by SpaceX in October. The first satellite that EchoStar has constructed with manufacturer Airbus, EchoStar 105/SES-11 will be launched by SpaceX on a flight-proven Falcon 9 rocket from Launch Complex 39A at Kennedy Space Center, Florida. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005539/en/ EchoStar 105/SES-11 Shipped from Toulouse to the Cape for SpaceX Launch (Photo: Business Wire) EchoStar 105/SES-11, a high-powered hybrid Ku and C-band communications satellite, is a dual-mission satellite for US-based operator EchoStar and Luxembourg-based
OT-Morpho Will Provide the Subscription Management Solution for Deutsche Telekom Group20.9.2017 08:41 | Pressemelding
OT-Morpho, a world leader in digital security and identification technologies, today announces that it has been selected by Deutsche Telekom AG (DTAG), a leading mobile network operator, to provide the first group wide subscription management solution, which has recently ensured the first commercial launch of a GSMA Phase 2 compliant consumer eSIM device in Germany and Croatia. DTAG’s choice relies on OT-Morpho’s highly innovative positioning and readiness on this technology and furthermore its engagement with major OEMs as a supplier of eSIMs. Indeed, OT-Morpho’s subscription management platform enables the secure download of the subscription into an eSIM, embedded or removable, already present in a device while ensuring the complete confidentiality and security of network data. OT-Morpho’s platform offers remote subscription provisioning services that are fully compliant w
Visa Announces Team Visa Roster for the Upcoming Olympic and Paralympic Winter Games20.9.2017 07:01 | Pressemelding
Visa (NYSE:V) today announced its global Team Visa roster for the Olympic and Paralympic Winter Games PyeongChang 2018, comprised of over 40 Olympians and Paralympians from 17 countries, including Mikaela Shiffrin (USA), Chloe Kim (USA), Mark McMorris (Canada), Gus Kenworthy (USA), Oksana Masters (USA), Lee, Sang Hwa (South Korea), Kamil Stoch (Poland), and Hilary Knight (USA). This team of Olympic and Paralympic hopefuls represent a diverse group of individuals representing a range of sports, from snowboarding and speed skating to ski jumping and figure skating. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005473/en/ Visa is excited to announce the #TeamVisa roster of athletes who are going for gold at #PyeongChang2018. (Photo: Business Wire) A global Olympic partner for more than 30 yea
Brooks Levitate with DNA AMP Delivers Infinite Energy20.9.2017 04:01 | Pressemelding
Based on seven years of Run Signature research, Brooks Running is launching the all new Levitate with DNA AMP—a shoe engineered to provide the most energy return of leading performance running shoes. The springy and responsive Brooks Levitate is available for pre-order beginning today at http://www.brooksrunning.com/en_us/brooks-levitate-running-shoes.html and will be available worldwide Sept. 30. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170919006747/en/ Brooks Levitate with DNA AMP Delivers Infinite Energy (Photo: Business Wire) “We’re pushing the limits of energy return with the new Brooks Levitate and are excited to unveil a shoe that has been engineered from the ground up to provide runners with an infinitely energetic experience,” said Carson Caprara, director of global product line ma
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom